Lyfspn is a physician-led venture-backed startup company working to invent novel therapies that will allow us to live longer, healthier lives. The Lyfspn team is passionate about bringing therapies to the world that find their basis in basic science research.
Lyfspn is currently planning to carry out a pilot study of our lead longevity promoting therapy candidate, a novel apheresis-based treatment.
Apheresis is an existing therapeutic modality which plays an important role in the management of many diseases including more than 50 autoimmune disorders, a number of rare neurologic conditions, and Alzheimer's disease.
Apheresis is emerging as a prevention and therapy for other age related medical conditions.
Please contact us to learn more about our pilot study.
Please provide us with your information and click submit.
We'll get right back to you.